{"id":"NCT02270736","sponsor":"Merz Pharmaceuticals GmbH","briefTitle":"Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability","officialTitle":"Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study With an Open-label Extension Period to Investigate the Efficacy and Safety of NT 201 in the Treatment of Children and Adolescents (2-17 Years) With Chronic Troublesome Sialorrhea Associated With Neurological Disorders, and/or Intellectual Disability","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-02-09","primaryCompletion":"2018-02-23","completion":"2019-05-07","firstPosted":"2014-10-21","resultsPosted":"2021-01-20","lastUpdate":"2021-08-10"},"enrollment":256,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Troublesome Sialorrhea","Cerebral Palsy","Stroke","Traumatic Brain Injury","Intellectual Disability"],"interventions":[{"type":"DRUG","name":"NT 201 Placebo","otherNames":[]},{"type":"DRUG","name":"NT 201","otherNames":["IncobotulinumtoxinA","Xeomin","Botulinum toxin type A (150 kiloDalton), free from complexing proteins"]}],"arms":[{"label":"Double-blind MP: Placebo (Age 6 to 17 Years)","type":"EXPERIMENTAL"},{"label":"Double-blind, MP: NT 201 (Age 6 to 17 Years)","type":"EXPERIMENTAL"},{"label":"Open-label, MP: NT 201 (Age 2 to 5 Years)","type":"EXPERIMENTAL"},{"label":"OLEX: NT 201 (Age 6 to 17 Years)","type":"EXPERIMENTAL"},{"label":"OLEX: NT 201 (Age 2 to 5 Years)","type":"EXPERIMENTAL"}],"summary":"The objective of this study is to investigate the efficacy and safety of NT 201 compared with placebo for the treatment of chronic troublesome sialorrhea associated with neurological disorders (e.g. cerebral palsy, traumatic brain injury) and/or intellectual disability in children and adolescents na√Øve to Botulinum neurotoxin treatment and aged 2-17 years.","primaryOutcome":{"measure":"Change From Baseline in Unstimulated Salivary Flow Rate (uSFR) at Week 4","timeFrame":"Baseline and Week 4","effectByArm":[{"arm":"Double-blind MP: Placebo (Age 6 to 17 Years)","deltaMin":-0.07,"sd":0.015},{"arm":"Double-blind, MP: NT 201 (Age 6 to 17 Years)","deltaMin":-0.14,"sd":0.012}],"pValues":[{"comp":"OG000 vs OG001","p":"= 0.0012"}]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":10},"locations":{"siteCount":31,"countries":["Georgia","Hungary","Poland","Russia","Serbia","Ukraine"]},"refs":{"pmids":["34341153","36136523"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":72},"commonTop":["Nasopharyngitis","Pharyngitis","Respiratory tract infection","Viral infection","Respiratory tract infection viral"]}}